vs
费森尤斯医疗（FMS）与Sotera Health Co（SHC）财务数据对比。点击上方公司名可切换其他公司
费森尤斯医疗的季度营收约是Sotera Health Co的18.0倍（$5.5B vs $303.4M）。Sotera Health Co净利率更高（11.5% vs 7.9%，领先3.6%）。Sotera Health Co同比增速更快（4.6% vs -0.3%）
费森尤斯医疗是德国知名医疗保健企业，核心业务为肾脏透析服务，在全球运营4171家门诊透析中心，服务约34.54万名患者。公司主要为终末期肾病患者提供治疗服务，该类患者需终身每周接受3次透析治疗以维持生命。
Sotera Health Co是全球领先的医疗安全解决方案提供商，面向医疗器械厂商、制药企业、食品及消费品公司提供灭菌服务、实验室分析检测与合规咨询支持，帮助客户满足监管要求，保障上市产品的使用安全。
FMS vs SHC — 直观对比
营收规模更大
FMS
是对方的18.0倍
$303.4M
营收增速更快
SHC
高出4.9%
-0.3%
净利率更高
SHC
高出3.6%
7.9%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $5.5B | $303.4M |
| 净利润 | $434.2M | $34.8M |
| 毛利率 | 27.4% | 54.7% |
| 营业利润率 | 11.7% | 23.2% |
| 净利率 | 7.9% | 11.5% |
| 营收同比 | -0.3% | 4.6% |
| 净利润同比 | 240.4% | 182.8% |
| 每股收益（稀释后） | — | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FMSSHC
| Q4 25 | $5.5B | $303.4M | ||
| Q3 25 | — | $311.3M | ||
| Q2 25 | — | $294.3M | ||
| Q1 25 | — | $254.5M | ||
| Q4 24 | $5.5B | $290.2M | ||
| Q3 24 | — | $285.5M | ||
| Q2 24 | — | $276.6M | ||
| Q1 24 | — | $248.2M |
净利润FMSSHC
| Q4 25 | $434.2M | $34.8M | ||
| Q3 25 | — | $48.4M | ||
| Q2 25 | — | $8.0M | ||
| Q1 25 | — | $-13.3M | ||
| Q4 24 | $127.6M | $12.3M | ||
| Q3 24 | — | $17.0M | ||
| Q2 24 | — | $8.8M | ||
| Q1 24 | — | $6.3M |
毛利率FMSSHC
| Q4 25 | 27.4% | 54.7% | ||
| Q3 25 | — | 57.0% | ||
| Q2 25 | — | 56.6% | ||
| Q1 25 | — | 53.2% | ||
| Q4 24 | 25.0% | 56.6% | ||
| Q3 24 | — | 55.4% | ||
| Q2 24 | — | 55.2% | ||
| Q1 24 | — | 51.2% |
营业利润率FMSSHC
| Q4 25 | 11.7% | 23.2% | ||
| Q3 25 | — | 23.4% | ||
| Q2 25 | — | 6.4% | ||
| Q1 25 | — | -5.8% | ||
| Q4 24 | 5.1% | 30.0% | ||
| Q3 24 | — | 28.2% | ||
| Q2 24 | — | 27.8% | ||
| Q1 24 | — | 21.4% |
净利率FMSSHC
| Q4 25 | 7.9% | 11.5% | ||
| Q3 25 | — | 15.5% | ||
| Q2 25 | — | 2.7% | ||
| Q1 25 | — | -5.2% | ||
| Q4 24 | 2.3% | 4.2% | ||
| Q3 24 | — | 6.0% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.5% |
每股收益（稀释后）FMSSHC
| Q4 25 | — | $0.12 | ||
| Q3 25 | — | $0.17 | ||
| Q2 25 | — | $0.03 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $0.05 | ||
| Q3 24 | — | $0.06 | ||
| Q2 24 | — | $0.03 | ||
| Q1 24 | — | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7B | $344.6M |
| 总债务越低越好 | — | $2.1B |
| 股东权益账面价值 | $15.4B | $606.0M |
| 总资产 | $33.5B | $3.3B |
| 负债/权益比越低杠杆越低 | — | 3.53× |
8季度趋势，按日历期对齐
现金及短期投资FMSSHC
| Q4 25 | $1.7B | $344.6M | ||
| Q3 25 | — | $299.2M | ||
| Q2 25 | — | $332.4M | ||
| Q1 25 | — | $304.4M | ||
| Q4 24 | $1.3B | $277.2M | ||
| Q3 24 | — | $306.7M | ||
| Q2 24 | — | $246.1M | ||
| Q1 24 | — | $261.1M |
总债务FMSSHC
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
股东权益FMSSHC
| Q4 25 | $15.4B | $606.0M | ||
| Q3 25 | — | $550.5M | ||
| Q2 25 | — | $511.3M | ||
| Q1 25 | — | $414.1M | ||
| Q4 24 | $17.0B | $404.9M | ||
| Q3 24 | — | $470.2M | ||
| Q2 24 | — | $422.8M | ||
| Q1 24 | — | $429.4M |
总资产FMSSHC
| Q4 25 | $33.5B | $3.3B | ||
| Q3 25 | — | $3.2B | ||
| Q2 25 | — | $3.2B | ||
| Q1 25 | — | $3.1B | ||
| Q4 24 | $36.3B | $3.1B | ||
| Q3 24 | — | $3.1B | ||
| Q2 24 | — | $3.1B | ||
| Q1 24 | — | $3.1B |
负债/权益比FMSSHC
| Q4 25 | — | 3.53× | ||
| Q3 25 | — | 3.89× | ||
| Q2 25 | — | 4.34× | ||
| Q1 25 | — | 5.36× | ||
| Q4 24 | — | 5.49× | ||
| Q3 24 | — | 4.73× | ||
| Q2 24 | — | 5.26× | ||
| Q1 24 | — | 5.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.9B | $103.1M |
| 自由现金流经营现金流 - 资本支出 | — | $52.4M |
| 自由现金流率自由现金流/营收 | — | 17.3% |
| 资本支出强度资本支出/营收 | — | 16.7% |
| 现金转化率经营现金流/净利润 | 6.67× | 2.96× |
| 过去12个月自由现金流最近4个季度 | — | $149.2M |
8季度趋势，按日历期对齐
经营现金流FMSSHC
| Q4 25 | $2.9B | $103.1M | ||
| Q3 25 | — | $71.2M | ||
| Q2 25 | — | $57.4M | ||
| Q1 25 | — | $55.5M | ||
| Q4 24 | $2.6B | $55.7M | ||
| Q3 24 | — | $97.5M | ||
| Q2 24 | — | $61.3M | ||
| Q1 24 | — | $9.7M |
自由现金流FMSSHC
| Q4 25 | — | $52.4M | ||
| Q3 25 | — | $35.0M | ||
| Q2 25 | — | $26.2M | ||
| Q1 25 | — | $35.6M | ||
| Q4 24 | — | $-10.2M | ||
| Q3 24 | — | $61.1M | ||
| Q2 24 | — | $19.4M | ||
| Q1 24 | — | $-25.2M |
自由现金流率FMSSHC
| Q4 25 | — | 17.3% | ||
| Q3 25 | — | 11.2% | ||
| Q2 25 | — | 8.9% | ||
| Q1 25 | — | 14.0% | ||
| Q4 24 | — | -3.5% | ||
| Q3 24 | — | 21.4% | ||
| Q2 24 | — | 7.0% | ||
| Q1 24 | — | -10.2% |
资本支出强度FMSSHC
| Q4 25 | — | 16.7% | ||
| Q3 25 | — | 11.6% | ||
| Q2 25 | — | 10.6% | ||
| Q1 25 | — | 7.8% | ||
| Q4 24 | — | 22.7% | ||
| Q3 24 | — | 12.7% | ||
| Q2 24 | — | 15.2% | ||
| Q1 24 | — | 14.1% |
现金转化率FMSSHC
| Q4 25 | 6.67× | 2.96× | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | — | 7.21× | ||
| Q1 25 | — | — | ||
| Q4 24 | 20.20× | 4.52× | ||
| Q3 24 | — | 5.73× | ||
| Q2 24 | — | 7.00× | ||
| Q1 24 | — | 1.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FMS
暂无分部数据
SHC
| Transferred At Point In Time | $198.4M | 65% |
| Nelson Labs | $55.2M | 18% |
| Nordion | $49.8M | 16% |
